Abstract:www.ccmjournal.org March 2013 • Volume 41 • Number 3 Aspiration is a common complication in hospitalized patients, which is usually associated with poor outcomes, especially in those with neuromuscular diseases, gastrointestinal or esophageal dysfunction, and loss of consciousness. The clinical manifestations of aspiration vary depending on volume and contents of aspiration as well as the host’s response. Considering quick deterioration of lung function due to chemical and bacterial insults after aspiration, it is critical to have an assay to detect and discriminate chemical and bacterial pneumonia to guide antibiotic treatment. Several biomarkers, such as pepsin and lipid laden alveolar macrophages have been identified as evidence of aspiration because both of them suggested lipid content from gastrointestinal tract, especially in children with gastro esophageal reflux and gastric contents aspiration–induced bronchopulmonary dysplasia in neonates (1). In adults patients, bronchoalveolar lavage (BAL) pepsin in intubated patients has been considered an indicator for aspiration of gastric contents and also a major risk factor for pneumonia (2, 3). To further diagnose etiology of aspiration pneumonia, serum procalcitonin (PCT), C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 (sTERM-1), and cytokines profiles (4) have been investigated for feasibility to discriminate bacterial aspiration pneumonia and chemical pneumonitis besides as a marker to diagnose aspiration. In addition, serial measurements of serum PCT was associated with the prognosis of pulmonary aspiration (5) and BAL sTREM-1 levels could be potentially useful in distinguishing BAL culture–positive from BAL culture–negative aspiration (6). However, both the sensitivity and specificity (76% and 38% for PCT using a threshold of 2.0 ng/ml, 65.8% and 91.9% for sTREM-1 using a threshold of 250 pg/ml) to diagnose aspiration pneumonia and chemical pneumonitis using above biomarker have not been widely accepted. In this issue of Critical Care Medicine, Weiss and colleagues (7) studied the role of BAL α-amylase in diagnosis of aspiration in a retrospective study. Total 296 BAL samples were collected within 72 hrs after endotracheal intubation from 280 mechanically ventilated patients in five medical centers, and the relationship between BAL amylase concentration and pre-intubation aspiration risk factors as well as the BAL microbial culture results were analyzed. What they found were 1) there was a strong association between BAL amylase concentration and traditional risk factors for aspiration; 2) BAL amylase concentration may predict bacterial pneumonia; 3) if BAL amylase concentration cutoff value was < 125 units/L, the sensitivity for predicting bacterial pneumonia was 70%, with a negative predictive value of 85%. If combined with clinical information, BAL amylase might be helpful in early diagnosis and the management of suspected aspiration. Actually, as early as in the 1980s, there was some evidence showing (8, 9) that BAL amylase was derived from oropharyngeal contents and aspiration or pulmonary complication. Unfortunately, no further clinical studies have been conducted to confirm above findings until Weiss et al revealed the significance of BAL amylase in diagnosing and differentiating bacterial pneumonia after aspiration with high sensitivity and negative predictive value. Nevertheless, this study does have some limitations as the author had addressed in the text, such as the absence of a gold standard to diagnose bacterial pneumonia and the potential confounding factors. Even though the amylase in BAL has a relatively long-lasting detection window, its dynamic changes of activity should not be neglected. Multiple quantitative detection of BAL amylase would be preferred other than one time measurement. In addition, BAL is an invasive approach which also needs special training before operation, the volume and location of BAL should be standardized to have comparison between different institutes. In some patients without artificial intubation, it is not practical to have BAL examination. Thus, given the current limitations, well-designed Cohort studies should be conducted to test whether this is a robust finding. In conclusion, notwithstanding the caveat, the results from this study may guide the clinical management of aspiration.

Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction

Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration

Utility of bile acids in large airway bronchial wash versus bronchoalveolar lavage as biomarkers of microaspiration in lung transplant recipients: a retrospective cohort study

The Lung Allograft Microbiome Associates with Pepsin, Inflammation, and Primary Graft Dysfunction

Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation

Proteomic Analysis of Primary Graft Dysfunction in Porcine Lung Transplantation Reveals Alveolar-Capillary Barrier Changes Underlying the High Particle Flow Rate in Exhaled Breath

Lung Allograft Microbiome Association with Gastroesophageal Reflux, Inflammation, and Allograft Dysfunction

The Controversy of Pepsinogen A/Pepsin A in Detecting Extra-Gastroesophageal Reflux

Bronchoalveolar lavage cytokine-based risk stratification of minimal acute rejection in clinically stable lung transplant recipients

A potential mechanism by which aspiration of duodenogastric fluid augments the risk for bronchiolitis obliterans syndrome after lung transplantation

Bile Acid Aspiration Associates with CLAD and Affects the Bronchial District Lipid Profile: Targeted Bile Acid Metabolomics and Lipidomics in Bronchial Washing

Evaluation of Donor Lungs for Transplantation: The Efficacy of Screening Bronchoscopy for Detecting Donor Aspiration and Its Relationship to the Resulting Allograft Function in Corresponding Recipients

Presence of Gastric Pepsinogen in the Trachea Is Associated with Altered Inflammation and Microbial Composition

Pepsin and amylase in oral and tracheal secretions: a pilot study

Amylase in Bronchoalveolar Lavage Fluid: a New Marker for Pulmonary Aspiration.

Pre-Lung transplant reflux testing demonstrates high prevalence of gastroesophageal reflux in cystic fibrosis and reduces chronic rejection risk

The Role of GERD Diagnosis and Treatment in Preventing Lung Function Decline After Pediatric Lung Transplantation

Noninvasive biomarkers for the detection of GERD-induced pulmonary injury

Plasma protein biomarkers for primary graft dysfunction after lung transplantation: a single-center cohort analysis

Systematic fungal biomarker or polymerase chain reaction testing in lung transplant recipients: Retrospective analysis to optimize their use

Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure